vs
Side-by-side financial comparison of Esperion Therapeutics, Inc. (ESPR) and INDEPENDENT BANK CORP (INDB). Click either name above to swap in a different company.
INDEPENDENT BANK CORP is the larger business by last-quarter revenue ($212.5M vs $168.4M, roughly 1.3× Esperion Therapeutics, Inc.). On growth, Esperion Therapeutics, Inc. posted the faster year-over-year revenue change (143.7% vs 46.9%). Over the past eight quarters, INDEPENDENT BANK CORP's revenue compounded faster (24.3% CAGR vs 10.6%).
Esperion Therapeutics, Inc. is a publicly traded American pharmaceutical company focused on the development of bempedoic acid, an orally available small molecule designed to lower elevated levels of LDL-C. The company is headquartered in Ann Arbor, Michigan.
Independent Bank is a bank headquartered in Grand Rapids, Michigan. The bank has 62 branches, all of which are in Michigan.
ESPR vs INDB — Head-to-Head
Income Statement — Q4 FY2025 vs Q4 FY2025
| Metric | | |
|---|---|---|
| Revenue | $168.4M | $212.5M |
| Net Profit | — | $75.3M |
| Gross Margin | — | — |
| Operating Margin | 50.6% | — |
| Net Margin | — | 35.5% |
| Revenue YoY | 143.7% | 46.9% |
| Net Profit YoY | — | 50.6% |
| EPS (diluted) | $0.32 | $1.51 |
Green = leading value per metric. Periods may differ when fiscal calendars don't align.
8-Quarter Revenue & Profit Trend
Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.
| Q4 25 | $168.4M | $212.5M | ||
| Q3 25 | $87.3M | $203.3M | ||
| Q2 25 | $82.4M | $147.5M | ||
| Q1 25 | $65.0M | $145.5M | ||
| Q4 24 | $69.1M | $144.7M | ||
| Q3 24 | $51.6M | $141.7M | ||
| Q2 24 | $73.8M | $137.9M | ||
| Q1 24 | $137.7M | $137.4M |
| Q4 25 | — | $75.3M | ||
| Q3 25 | $-31.3M | $34.3M | ||
| Q2 25 | $-12.7M | $51.1M | ||
| Q1 25 | $-40.5M | $44.4M | ||
| Q4 24 | — | $50.0M | ||
| Q3 24 | $-29.5M | $42.9M | ||
| Q2 24 | $-61.9M | $51.3M | ||
| Q1 24 | $61.0M | $47.8M |
| Q4 25 | 50.6% | — | ||
| Q3 25 | -11.4% | 21.8% | ||
| Q2 25 | 8.6% | 44.6% | ||
| Q1 25 | -34.0% | 39.3% | ||
| Q4 24 | -6.4% | — | ||
| Q3 24 | -31.0% | 39.0% | ||
| Q2 24 | 3.5% | 48.1% | ||
| Q1 24 | 52.5% | 45.5% |
| Q4 25 | — | 35.5% | ||
| Q3 25 | -35.9% | 16.8% | ||
| Q2 25 | -15.4% | 34.6% | ||
| Q1 25 | -62.2% | 30.5% | ||
| Q4 24 | — | 34.6% | ||
| Q3 24 | -57.2% | 30.3% | ||
| Q2 24 | -83.9% | 37.2% | ||
| Q1 24 | 44.3% | 34.8% |
| Q4 25 | $0.32 | $1.51 | ||
| Q3 25 | $-0.16 | $0.69 | ||
| Q2 25 | $-0.06 | $1.20 | ||
| Q1 25 | $-0.21 | $1.04 | ||
| Q4 24 | $-0.14 | $1.18 | ||
| Q3 24 | $-0.15 | $1.01 | ||
| Q2 24 | $-0.33 | $1.21 | ||
| Q1 24 | $0.34 | $1.12 |
Balance Sheet & Financial Strength
Snapshot of each company's liquidity, leverage and book value from the latest quarter.
| Metric | | |
|---|---|---|
| Cash + ST InvestmentsLiquidity on hand | $167.9M | — |
| Total DebtLower is stronger | — | — |
| Stockholders' EquityBook value | $-302.0M | $3.6B |
| Total Assets | $465.9M | $24.9B |
| Debt / EquityLower = less leverage | — | — |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $167.9M | — | ||
| Q3 25 | $92.4M | — | ||
| Q2 25 | $86.1M | — | ||
| Q1 25 | $114.6M | — | ||
| Q4 24 | $144.8M | — | ||
| Q3 24 | $144.7M | — | ||
| Q2 24 | $189.3M | — | ||
| Q1 24 | $226.6M | — |
| Q4 25 | $-302.0M | $3.6B | ||
| Q3 25 | $-451.4M | $3.5B | ||
| Q2 25 | $-433.5M | $3.1B | ||
| Q1 25 | $-426.2M | $3.0B | ||
| Q4 24 | $-388.7M | $3.0B | ||
| Q3 24 | $-370.2M | $3.0B | ||
| Q2 24 | $-344.2M | $2.9B | ||
| Q1 24 | $-294.3M | $2.9B |
| Q4 25 | $465.9M | $24.9B | ||
| Q3 25 | $364.0M | $25.0B | ||
| Q2 25 | $347.1M | $20.0B | ||
| Q1 25 | $324.0M | $19.9B | ||
| Q4 24 | $343.8M | $19.4B | ||
| Q3 24 | $314.1M | $19.4B | ||
| Q2 24 | $352.3M | $19.4B | ||
| Q1 24 | $373.1M | $19.3B |
Cash Flow & Capital Efficiency
How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.
| Metric | | |
|---|---|---|
| Operating Cash FlowLast quarter | $45.2M | $78.9M |
| Free Cash FlowOCF − Capex | — | $75.5M |
| FCF MarginFCF / Revenue | — | 35.5% |
| Capex IntensityCapex / Revenue | 0.0% | 1.6% |
| Cash ConversionOCF / Net Profit | — | 1.05× |
| TTM Free Cash FlowTrailing 4 quarters | — | $239.0M |
8-quarter trend — quarters aligned by calendar period.
| Q4 25 | $45.2M | $78.9M | ||
| Q3 25 | $-4.3M | $52.2M | ||
| Q2 25 | $-31.4M | $106.7M | ||
| Q1 25 | $-22.6M | $13.3M | ||
| Q4 24 | $-35.0M | $42.9M | ||
| Q3 24 | $-35.3M | $70.2M | ||
| Q2 24 | $-7.2M | $65.6M | ||
| Q1 24 | $53.8M | $51.1M |
| Q4 25 | — | $75.5M | ||
| Q3 25 | — | $49.7M | ||
| Q2 25 | — | $102.5M | ||
| Q1 25 | — | $11.3M | ||
| Q4 24 | — | $36.5M | ||
| Q3 24 | $-35.5M | $64.4M | ||
| Q2 24 | $-7.3M | $61.9M | ||
| Q1 24 | $53.8M | $46.7M |
| Q4 25 | — | 35.5% | ||
| Q3 25 | — | 24.4% | ||
| Q2 25 | — | 69.5% | ||
| Q1 25 | — | 7.8% | ||
| Q4 24 | — | 25.2% | ||
| Q3 24 | -68.7% | 45.4% | ||
| Q2 24 | -9.9% | 44.9% | ||
| Q1 24 | 39.0% | 34.0% |
| Q4 25 | 0.0% | 1.6% | ||
| Q3 25 | 0.0% | 1.2% | ||
| Q2 25 | 0.0% | 2.9% | ||
| Q1 25 | 0.0% | 1.4% | ||
| Q4 24 | 0.0% | 4.4% | ||
| Q3 24 | 0.3% | 4.1% | ||
| Q2 24 | 0.1% | 2.7% | ||
| Q1 24 | 0.1% | 3.2% |
| Q4 25 | — | 1.05× | ||
| Q3 25 | — | 1.52× | ||
| Q2 25 | — | 2.09× | ||
| Q1 25 | — | 0.30× | ||
| Q4 24 | — | 0.86× | ||
| Q3 24 | — | 1.64× | ||
| Q2 24 | — | 1.28× | ||
| Q1 24 | 0.88× | 1.07× |
Financial Flow Comparison
Revenue → gross profit → operating profit → net profit for each company.
Revenue Breakdown by Segment
ESPR
| Collaboration Revenue | $124.7M | 74% |
| Products | $43.7M | 26% |
INDB
Segment breakdown not available.
